WCM/EADO 2021 | Combining checkpoint blockade therapies in melanoma
Jedd Wolchok, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an update on the Phase III CheckMate 067 study (NCT01844505) of nivolumab alone or in combination with ipilimumab versus ipilimumab alone in first-line metastatic melanoma. At 5-year follow-up, a sustained improvement in survival was reported in patient groups that received nivolumab compared to ipilimumab alone. Given the high rate of toxicities associated with the combination therapy, adaptive dosing is being evaluated in a Phase II study (NCT03122522), in which patients that respond well following two doses of the combination therapy are crossed over to nivolumab alone. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.
Disclosures
Jedd Wolchok, MD, PhD has participated in consultancy work for Adaptive Biotech, Amgen, Apricity, Ascentage Pharma, Arsenal IO, Astellas, AstraZeneca, Bayer, Beigene, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Daiichi Sankyo, Dragonfly, Eli Lilly, Elucida, F Star, Georgiamune, Idera, Imvaq, Kyowa Hakko Kirin, Linneaus, Maverick Therapeutics, Merck, Neon Therapeutics, Polynoma, Psioxus, Recepta, Takara Bio, Trieza, Truvax, Trishula, Sellas, Serametrix, Surface Oncology, Syndax, Syntalogic and Werewolf Therapeutics; has received grant/research support from Bristol Myers Squibb and Sephora; and is an equity holder of Tizona Pharmaceuticals, Adaptive Biotechnologies, Imvaq, Beigene, Linneaus, Apricity, Arsenal IO and Georgiamune.
